The product of ABL-BCR fusion appears to be an abnormal kinase that stimulates the proliferation of myeloid cells leading to chronic myelogenous leukaemia (CML) [84]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.